FDA grants fast track designation for Ambrx’s ARX517 for the treatment of metastatic castration-resistant prostate cancer. News release. Ambrx …
FDA Gives Fast Track Designation to ARX517 in Metastatic CRPC – Cancer Network
Share This Story, Choose Your Platform!
About the Author:
